Bastion Trading, owning nearly 10% of SkyAI, opposes the company's $201 million tender offer at $3 per share, citing concerns over governance, disclosure, and the large sale of about 70% of SkyAI's Solana treasury. Bastion demands a higher tender price of at least $3.50, more transparency on the timing and details of Solana sales, and board changes including new independent directors. The dispute highlights shareholder unease over SkyAI's capital strategy and could impact whether the tender offer succeeds.
SkyAI's recent sale of about 70% of its Solana treasury is a key point in the ongoing shareholder dispute. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 16, 2026 02:04 WIB: out of 50 major cryptocurrencies, 30 rose and 19 fell. Notable movers include COTI at Rp205 with a 2.96% decrease and strong buy interest (96% buy orders), COMP at Rp396.156 down 2.92% with more sell orders (55%), and XTZ at Rp5.729 up 2.78% with predominantly sell orders (77%).
Citigroup increased its price target for Krystal Biotech to $416 from $386, citing strong Q2 revenue of $119.2 million from its approved product Vyjuvek and encouraging early clinical data for KB113, a treatment for basal cell carcinomas in Gorlin sy...
Bank7 Corp. reported Q3 2026 earnings of $1.06 per share, slightly beating analyst estimates, while revenue of $23.37 million fell short and declined year-over-year. Despite lower revenue and earnings compared to last year, the bank continues to grow...
Scotiabank increased its price target for Targa Resources to $319 from $314, indicating a potential 12.7% upside from the current share price of around $283. Targa Resources, a key player in the midstream energy sector, is recognized as a top momentu...
Ericsson reported better-than-expected Q3 earnings with EPS of $0.18 and revenue of $5.91 billion, driven by strong demand in its mobile network segment. The Networks division showed 9% organic growth and a gross margin above guidance, but overall op...
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
